| PRIMARY INFORMATION |
|---|
| ID | 1521 |
| PMID | 16621488 |
| Year | 2006 |
| Sequence | Aa-MeLeu-MeLeu-MeVal-3-hydroxy-N,4-dimethyl-
L-2-amino-6-octenoyl-Abu-MeGly-MeLeu-V-MeLeu |
| Name | Cyclosporin A (CysA) bearing reverse hexagonal phase |
| Length | 11 |
| N-Terminal Modification | Free |
| C-Terminal Modification | Free |
| Linear/ Cyclic | Cyclic (head to tail) |
| Chirality | Mix |
| Chemical Modification | Abu= amino butyric acid, MeLeu=N-methyl-Leucine, MeVal=N-methyl-Valine |
| Origin of Peptide | An immune-suppressant obtained from a type of soil fungus, Tolypocladium inflatum. |
| Nature of Peptide/Cargo | Cyclic and highly lipophilic peptide that presents poor skin penetration capacity and works as an immune-suppressant agent |
| Mechanism | An immune-suppressant obtained from a type of soil fungus, Tolypocladium inflatum. |
| Cargo Sequence/Structure | None |
Name of cargo
| Not applicable |
| Assay | Franz diffusion cell, HPLC |
| Enhancer | Not mentioned |
| Properties of enhancer | Not mentioned |
| Concentration | 100mg (Monoolein:Oleic acid:Cyclosporin A:Water=75:5:4:16/Control=Cyclosporin A in olive oil 4% w/w) |
| Incubation time | 6 hours |
| Tissue permeability (value with units) | Amount of applied dose/cm2 present in stratum corneum=1.5%, 1.3%(Control); Amount of applied dose/cm2 present in epidermis without stratum corneum + dermis=1.1%, 0.38%(Control) |
| Tissue Sample | In-vitro model of porcine ear skin |
| Ex vivo/In vivo/In vitro | in vitro |
| SECONDARY INFORMATION |
|---|
| STRUCTURE | |
| SMILES | N.A. |
